medicaid glp-1 What to Know About the BALANCE Model for GLP-1s in Medicare and and the Medicare Bridge Biden Proposes Coverage of Obesity

Going from 2 mg directly to 8 mg, or from 4 mg to 12 mg, dramatically increases the risk of severe gastrointestinal events and potential complications

In general, without knowing what Medicaid and Medicare generally are currently paying for these drugs on net, it is uncertain whether the lower prices that will be made available to state Medicaid programs and Part D plans under the BALANCE Model for currently covered uses of GLP-1s will generate enough savings to offset the additional costs from expanded use of these medications for obesity

This biological limitation is one of the primary reasons experts remain cautious when patients ask whether GLP-1 patches work compared to injectable GLP-1 therapy

2 Patients should be advised about the signs and symptoms of pancreatitis, even though this adverse event is considered to be rare

This hormone plays a key role in regulating blood sugar levels, appetite, and digestion

Health at every size [archived link] is one approach suggested for making healthcare more inclusive